Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
poly-ICLC + peptide-pulsed dendritic cells
- Development stage
- Unknown
- Lead developer
- Medical University of South Carolina
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intramuscular
01
Overview
A combination investigational cancer vaccine regimen consisting of autologous dendritic cells (DCs) pulsed with defined tumor-associated antigen peptides, administered together with the toll-like receptor 3 agonist poly-ICLC (stabilized polyinosinic-polycytidylic acid with poly-L-lysine and carboxymethylcellulose). The DC component presents class I–restricted peptides to prime tumor-specific CD8 T cells, while poly-ICLC acts as an immune adjuvant to enhance DC activation and type I interferon–driven innate and adaptive responses. In a phase I study in HLA-A2 positive pancreatic adenocarcinoma, DCs were pulsed with peptides from hTERT, CEA, and survivin; the regimen was safe and induced measurable antigen-specific T cells, with some patients achieving stable disease.[3][1][2]
- Other names
- poly(IC:LC) + peptide-pulsed autologous dendritic cells
02
Targets
IFIH1 (MDA5)MHC I (MHC class I})DDX58 (Retinoic acid-inducible gene I protein)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on poly-ICLC + peptide-pulsed dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on poly-ICLC + peptide-pulsed dendritic cells.